176 -2 (88) 2026 - Artikova S.G., Valieva Z.S. - INTEGRATIVE APPROACH TO THE DIAGNOSIS OF LIVER FIBROSIS IN THE PROGRESSION OF METABOLIC DYSFUNCTION–ASSOCIATED FATTY LIVER DISEASE

INTEGRATIVE APPROACH TO THE DIAGNOSIS OF LIVER FIBROSIS IN THE PROGRESSION OF METABOLIC DYSFUNCTION–ASSOCIATED FATTY LIVER DISEASE

Artikova S.G. - Andijan State Medical Institute

Valieva Z.S. - Andijan State Medical Institute

Isakova D.Z. - Andijan State Medical Institute

Yunusova Z.V. - Andijan State Medical Institute

Resume

Metabolic dysfunction–associated fatty liver disease (MAFLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to obesity, type 2 diabetes mellitus, and metabolic syndrome. Liver fibrosis represents the principal determinant of disease progression, clinical outcomes, and liver-related mortality in MAFLD. Accurate and timely assessment of fibrosis is therefore critical for risk stratification and therapeutic decision-making. This article reviews current invasive and non-invasive diagnostic modalities for liver fibrosis in MAFLD and highlights the scientific rationale for an integrative diagnostic approach that combines clinical, laboratory, and imaging data to improve diagnostic accuracy and prognostic value.

Keywords: MAFLD, liver fibrosis, non-invasive diagnostics, elastography, integrative approach

First page

953

Last page

957

For citation:Artikova S.G., Valieva Z.S., Isakova D.Z., Yunusova Z.V. - INTEGRATIVE APPROACH TO THE DIAGNOSIS OF LIVER FIBROSIS IN THE PROGRESSION OF METABOLIC DYSFUNCTION–ASSOCIATED FATTY LIVER DISEASE//New Day in Medicine 2(88)2026 953-957 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–344. doi:10.1038/nrgastro.2013.41.
2. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987–1000. doi:10.1002/hep.20920.
3. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):47–64. doi:10.1016/j.jhep.2014.12.012.
4. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211–218. doi:10.1136/flgastro-2013-100403.
5. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039.
6. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9.
7. Lazarus JV, Mark HE, Anstee QM, et al. Global epidemiology of non-alcoholic fatty liver disease and perspectives on current status and future developments. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–308. doi:10.1038/s41575-020-00381-z.
8. Loomba R, Adams LA. Advances in NAFLD therapeutics. Nat Rev Gastroenterol Hepatol. 2020;17(1):11–13. doi:10.1038/s41575-019-0225-2.
9. Loomba R, Friedman SL, Shulman GI. Emerging mechanisms and potential therapeutics for NAFLD-related fibrosis. Hepatology. 2021;74(2):616–629. doi:10.1002/hep.31629.
10. Mantovani A, Byrne CD, Scorletti E, et al. Complications and outcomes of NAFLD and NASH. Nat Rev Gastroenterol Hepatol. 2021;18(4):257–267. doi:10.1038/s41575-020-00393-9.

    file

    download